Table SII. Demographic baseline characteristics of patients with psoriasis in both biologic and control group among different registries

Demographics	Biologics		Classic drugs	
	Patients n	Mean (95% CI)	Patients n	Mean (95% CI)
Mean age				
AMC psoriasis registry, The Netherlands	194	50.6 (48.8–52.4)	NA	NA
Australian Psoriasis	475	49.8 (48.6–51.0)	29	50.7 (45.2–56.2)
Biobadaderm, Spain	793	43.9 (42.9–44.8)	632	45.9 (44.8–47.12)
Clalit Health Service, Israel	554	52.3 (51.1–53.5)	3,204	53.0 (52.4–53.6)
Dermbio, Denmark	1,083	45.3 (44.5–46.1)	161	43.2 (41.2–45.3)
PsoBest, Germany	378	48.4 (47.0– 49.8)	1,167	46.9 (46.1–47.8)
Psocare, Italy	6,191	47.8 (47.5–48.2)	5,371	49.1 (48.7–49.5)
Percentage of males				
AMC psoriasis registry, The Netherlands	120	61.9 (55.0–68.7)	NA	NA
Australian Psoriasis	319	66.9 (62.7–71.1)	19	65.5 (48.2–82.8)
Biobadaderm, Spain	502	63.3 (59.9–66.7)	369	58.4 (54.5–62.2)
Clalit Health Service, Israel	286	51.6 (47.5–55.8)	1,811	56.5 (54.8–58.2)
Dermbio, Denmark	686	63.3 (60.5–66.2)	93	57.8 (50.1–65.4)
PsoBest, Germany	235	61.8 (57.0–66.7)	1,811	57.3 (54.4–60.1)
Psocare, Italy	4,173	67.4 (66.2–68.6)	3,535	65.8 (64.5–67.1)
Percentage of current drinkers				
Australian Psoriasis	227	74.2 (69.3–79.1)	7	63.6 (35.2–92.1)
Biobadaderm, Spain	176	28.8 (25.2–32.4)	153	31.1 (27.0–35.2)
PsoBest, Germany	19	5.0 (2.8–7.2)	45	3.8 (2.7–4.9)
Psocare, Italy	2,160	34.9 (33.7–36.1)	1,962	36.5 (35.2–37.8)
Percentage of current smokers				
Australian Psoriasis	30	10.5 (7.0–14.1)	1	33.3 (−20.0–86.7)
Biobadaderm, Spain	232	35.7 (32.1–39.4)	228	41.8 (37.6–45.9)
Clalit Health Service, Israel	137	24.7 (21.1–28.3)	862	27.2 (25.7–28.8)
PsoBest, Germany	146	38.4 (33.5–43.3)	507	43.3 (40.5–46.2)
Psocare, Italy	2,357	38.1 (36.9–39.3)	2,101	39.1 (37.8–40.4)
Mean body mass index				
AM, psoriasis registry, The Netherlands	167	28.7 (27.7–29.7)	NA	NA
Australian Psoriasis	367	29.2 (28.4–30.0)	24	30.0 (27.4–32.6)
Biobadaderm, Spain	626	27.9 (27.5–28.4)	537	27.6 (27.2–28.0)
Clalit Health Service, Israel	548	30.5 (28.7–32.3)	3,141	29.1 (28.6–29.6)
Dermbio, Denmark	404	28.9 (28.1–29.7)	50	27.4 (25.9–28.9)
PsoBest, Germany	379	28.3 (27.8–28.8)	1,163	27.9 (27.5–28.3)
Psocare, Italy	5,869	27.2 (27.1–27.3)	5,138	26.8 (26.7–26.9)

CI: confidence interval; NA: not available; AMC: Academic Medical Center.